Trial
NCT03726333
Hepatic Impairment Study for Lorlatinib in Cancer Patients
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Advanced Cancers
Intervention
lorlatinib
Why stopped
The study stopped due to lack of enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-21